CONCLUSIONS
This study further confirms the safety of COVID-19 vaccination in the
neuroimmune disease population, especially those with autoimmune
neurological conditions. Stable patients with neuroimmune disorders
should be encouraged to receive COVID-19 vaccination. Further research
should monitor for serious adverse events following vaccination and the
long-term impact of vaccination on patients with neuroimmune diseases.
Abbreviations: ANC:autoimmune neurological conditions;
SARS-CoV-2 :severe acute respiratory syndrome type 2 coronavirus; MS:
multiple sclerosis; MG: myasthenia gravis; NMOSD: neuromyelitis optica
spectrum disorder; GBS: Guillain-Barre syndrome; CIDP: chronic
inflammatory demyelinating polyneuropathy; IST: immunosuppressive
therapy; MMN: multifocal motor neuropathy